Trial Profile

Phase IIa trial of polysialylated erythropoietin (ErepoXen) in patients with chronic kidney disease who are undergoing dialysis.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jul 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant erythropoietin (Primary)
Indications Anaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

02 Dec 2014 Full data analysis of the trial is expected to be completed by the end of the third quarter of 2015, according to an Aerie Pharmaceuticals media release.
02 Dec 2014 Results for the second cohort are expected in the first quarter of 2015, according to a Xenetic Biosciences media release.
02 Dec 2014 Dosing of the second cohort has been completed and enrolment in the third cohort has begun, according to a Xenetic Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com